107 related articles for article (PubMed ID: 32405728)
1. [Molecular predictors for the course of disease and individualized therapy in pancreatic cancer].
Damanakis AI; Gebauer F; Bruns CJ
Chirurg; 2020 Aug; 91(8):642-649. PubMed ID: 32405728
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.
Oshima M; Okano K; Muraki S; Haba R; Maeba T; Suzuki Y; Yachida S
Ann Surg; 2013 Aug; 258(2):336-46. PubMed ID: 23470568
[TBL] [Abstract][Full Text] [Related]
3. Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer.
Hayashi H; Kohno T; Ueno H; Hiraoka N; Kondo S; Saito M; Shimada Y; Ichikawa H; Kato M; Shibata T; Morizane C; Sakamoto Y; Shimada K; Komatsu Y; Sakamoto N; Okusaka T
Pancreas; 2017 Mar; 46(3):335-340. PubMed ID: 28099251
[TBL] [Abstract][Full Text] [Related]
4. Genetics and Biology of Pancreatic Ductal Adenocarcinoma.
Dunne RF; Hezel AF
Hematol Oncol Clin North Am; 2015 Aug; 29(4):595-608. PubMed ID: 26226899
[TBL] [Abstract][Full Text] [Related]
5. [Prognostic value of important driver gene mutations in patients with radical resection of pancreatic cancer].
Shen J; Gao SZ; Wang H; Shi XH; Li B; Pan YQ; Shen S; Shao Z; Guo SW; Jin G
Zhonghua Wai Ke Za Zhi; 2019 Nov; 57(11):840-847. PubMed ID: 31694133
[No Abstract] [Full Text] [Related]
6. K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma.
Kawesha A; Ghaneh P; Andrén-Sandberg A; Ograed D; Skar R; Dawiskiba S; Evans JD; Campbell F; Lemoine N; Neoptolemos JP
Int J Cancer; 2000 Nov; 89(6):469-74. PubMed ID: 11102889
[TBL] [Abstract][Full Text] [Related]
7. Molecular, morphological and survival analysis of 177 resected pancreatic ductal adenocarcinomas (PDACs): Identification of prognostic subtypes.
Schlitter AM; Segler A; Steiger K; Michalski CW; Jäger C; Konukiewitz B; Pfarr N; Endris V; Bettstetter M; Kong B; Regel I; Kleeff J; Klöppel G; Esposito I
Sci Rep; 2017 Feb; 7():41064. PubMed ID: 28145465
[TBL] [Abstract][Full Text] [Related]
8. [Genetic aspects of pancreatic cancer].
Grigor'eva IN; Efimova OV; Suvorova TS; Tov NL
Eksp Klin Gastroenterol; 2014; (10):70-6. PubMed ID: 25911935
[TBL] [Abstract][Full Text] [Related]
9. Pancreatic tumours: molecular pathways implicated in ductal cancer are involved in ampullary but not in exocrine nonductal or endocrine tumorigenesis.
Moore PS; Orlandini S; Zamboni G; Capelli P; Rigaud G; Falconi M; Bassi C; Lemoine NR; Scarpa A
Br J Cancer; 2001 Jan; 84(2):253-62. PubMed ID: 11161385
[TBL] [Abstract][Full Text] [Related]
10. Long-term survivors of pancreatic adenocarcinoma show low rates of genetic alterations in KRAS, TP53 and SMAD4.
Masetti M; Acquaviva G; Visani M; Tallini G; Fornelli A; Ragazzi M; Vasuri F; Grifoni D; Di Giacomo S; Fiorino S; Lombardi R; Tuminati D; Ravaioli M; Fabbri C; Bacchi-Reggiani ML; Pession A; Jovine E; de Biase D
Cancer Biomark; 2018 Feb; 21(2):323-334. PubMed ID: 29103024
[TBL] [Abstract][Full Text] [Related]
11. Combined targeting of TGF-β, EGFR and HER2 suppresses lymphangiogenesis and metastasis in a pancreatic cancer model.
Gore J; Imasuen-Williams IE; Conteh AM; Craven KE; Cheng M; Korc M
Cancer Lett; 2016 Aug; 379(1):143-53. PubMed ID: 27267807
[TBL] [Abstract][Full Text] [Related]
12. Dramatic response of FOLFIRINOX regimen in a collision pancreatic adenocarcinoma patient with a germline BRCA2 mutation: a case report.
Shimmura H; Kuramochi H; Jibiki N; Katagiri S; Nishino T; Araida T
Jpn J Clin Oncol; 2019 Dec; 49(11):1049-1054. PubMed ID: 31612916
[TBL] [Abstract][Full Text] [Related]
13. Molecular pathobiology of pancreatic adenocarcinoma.
Mangray S; King TC
Front Biosci; 1998 Nov; 3():D1148-60. PubMed ID: 9820739
[TBL] [Abstract][Full Text] [Related]
14. Clinical study of genomic drivers in pancreatic ductal adenocarcinoma.
Barrett MT; Deiotte R; Lenkiewicz E; Malasi S; Holley T; Evers L; Posner RG; Jones T; Han H; Sausen M; Velculescu VE; Drebin J; O'Dwyer P; Jameson G; Ramanathan RK; Von Hoff DD
Br J Cancer; 2017 Aug; 117(4):572-582. PubMed ID: 28720843
[TBL] [Abstract][Full Text] [Related]
15. Aberrant p16(INK4A) and DPC4/Smad4 expression in intraductal papillary mucinous tumours of the pancreas is associated with invasive ductal adenocarcinoma.
Biankin AV; Biankin SA; Kench JG; Morey AL; Lee CS; Head DR; Eckstein RP; Hugh TB; Henshall SM; Sutherland RL
Gut; 2002 Jun; 50(6):861-8. PubMed ID: 12010891
[TBL] [Abstract][Full Text] [Related]
16. ATM-deficiency increases genomic instability and metastatic potential in a mouse model of pancreatic cancer.
Drosos Y; Escobar D; Chiang MY; Roys K; Valentine V; Valentine MB; Rehg JE; Sahai V; Begley LA; Ye J; Paul L; McKinnon PJ; Sosa-Pineda B
Sci Rep; 2017 Sep; 7(1):11144. PubMed ID: 28894253
[TBL] [Abstract][Full Text] [Related]
17. Genetic abnormalities in pancreatic cancer.
Moore PS; Beghelli S; Zamboni G; Scarpa A
Mol Cancer; 2003 Jan; 2():7. PubMed ID: 12537585
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of clinical relevance of examining K-ras, p16 and p53 mutations along with allelic losses at 9p and 18q in EUS-guided fine needle aspiration samples of patients with chronic pancreatitis and pancreatic cancer.
Salek C; Benesova L; Zavoral M; Nosek V; Kasperova L; Ryska M; Strnad R; Traboulsi E; Minarik M
World J Gastroenterol; 2007 Jul; 13(27):3714-20. PubMed ID: 17659731
[TBL] [Abstract][Full Text] [Related]
19. Integrated Genomic and Immunophenotypic Classification of Pancreatic Cancer Reveals Three Distinct Subtypes with Prognostic/Predictive Significance.
Wartenberg M; Cibin S; Zlobec I; Vassella E; Eppenberger-Castori S; Terracciano L; Eichmann MD; Worni M; Gloor B; Perren A; Karamitopoulou E
Clin Cancer Res; 2018 Sep; 24(18):4444-4454. PubMed ID: 29661773
[No Abstract] [Full Text] [Related]
20. Pancreatic carcinoma in carriers of a specific 19 base pair deletion of CDKN2A/p16 (p16-leiden).
de vos tot Nederveen Cappel WH; Offerhaus GJ; van Puijenbroek M; Caspers E; Gruis NA; De Snoo FA; Lamers CB; Griffioen G; Bergman W; Vasen HF; Morreau H
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3598-605. PubMed ID: 14506146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
